Aktis Oncology, Inc.
AKTSNASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $869.87M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $14.72$34.19
- Volume (live)
- -
- Avg. volume (3M)
- 466.35K
Aktis Oncology (AKTS) Stock Price & Financial Analysis
Aktis Oncology Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $15.65 - $16.61 |
|---|---|
| 52-Week High | $34.19 |
| 52-Week Low | $14.72 |
| Open | $16.50 |
| Volume (last close) | 241.57K |
| Average Volume (3M) | 466.35K |
| Revenue (TTM) | 10.06M |
|---|---|
| Net Income (TTM) | -73.14M |
| Free Cash Flow (TTM) | -84.57M |
| EPS (TTM) | −$1.39 |
| Profit Margin | -727.04% |
| Operating Margin | -866.63% |
| Return on Equity (ROE) | -15.09% |
| Debt to Equity | 0.02 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 869.87M |
|---|---|
| Shares Outstanding | 55.30M |
| Price to Sales (P/S) | 86.47 |
| Price to Book (P/B) | 1.79 |
| EV/EBITDA | -10.14 |
| 50-Day MA | $21.88 |
|---|
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
Aktis Oncology at a Glance
As of the Oct 23, 2026 close, Aktis Oncology (AKTS) has a market capitalization of $869.87M. The stock trades at 86.5× sales. Over the trailing twelve months it lost $73.14M on revenue of $10.06M and burned $84.57M of free cash flow. Revenue grew 336.9% year over year.
As of its latest reported balance sheet, it holds $82.49M in cash and securities against $11.24M of debt, a net cash position of $71.25M.
Aktis Oncology does not currently pay a dividend.
At $15.73 (the Oct 23, 2026 close) it sits near the bottom of its 52-week range of $14.72 to $34.19.
Based on 6 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $35.80, 127.6% above the Oct 23, 2026 close.
Frequently Asked Questions About Aktis Oncology
What is the current stock price for AKTS?
As of the Oct 23, 2026 close, AKTS stock trades at $15.73. The 52-week range is $14.72–$34.19, with a day range of $15.65–$16.61.
What is the P/E ratio for AKTS?
The P/E ratio (Price-to-Earnings) for AKTS is shown in the Key Statistics section. This valuation metric helps compare Aktis Oncology, Inc. to industry peers.
Does AKTS pay dividends?
Aktis Oncology does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for AKTS?
Based on ratings from 6 professional analysts over the last 90 days, the consensus for AKTS is Buy. The average 12-month price target is $35.80, a 127.6% upside from the Oct 23, 2026 close of $15.73.
What is the market cap of AKTS?
As of the Oct 23, 2026 close, Aktis Oncology's market capitalization is $869.9M, classifying it as a small-cap company. Aktis Oncology operates in the Healthcare sector within the Biotechnology industry.